Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 3,600 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $320.45, for a total value of $1,153,620.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $41,658.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Stock Down 0.6 %

Shares of United Therapeutics stock opened at $317.05 on Wednesday. The business has a fifty day simple moving average of $278.12 and a 200 day simple moving average of $244.90. The stock has a market cap of $14.06 billion, a PE ratio of 14.99, a price-to-earnings-growth ratio of 1.40 and a beta of 0.55. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $325.00.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.63 by $0.54. The company had revenue of $677.70 million during the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The company’s revenue for the quarter was up 33.7% compared to the same quarter last year. During the same period in the previous year, the company earned $4.86 EPS. Research analysts predict that United Therapeutics Co. will post 24.73 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

Several large investors have recently bought and sold shares of UTHR. Blue Trust Inc. grew its holdings in shares of United Therapeutics by 10.0% in the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 46 shares during the period. MBM Wealth Consultants LLC lifted its holdings in United Therapeutics by 2.7% during the first quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company’s stock worth $515,000 after acquiring an additional 59 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in United Therapeutics by 1.6% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,892 shares of the biotechnology company’s stock valued at $856,000 after acquiring an additional 61 shares during the period. Janiczek Wealth Management LLC increased its holdings in shares of United Therapeutics by 21.1% in the first quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 84 shares in the last quarter. Finally, Compass Ion Advisors LLC raised its position in shares of United Therapeutics by 3.6% during the first quarter. Compass Ion Advisors LLC now owns 2,892 shares of the biotechnology company’s stock worth $664,000 after purchasing an additional 101 shares during the period. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of research analyst reports. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 20th. HC Wainwright reissued a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a research note on Thursday, May 2nd. JPMorgan Chase & Co. boosted their price objective on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 21st. The Goldman Sachs Group increased their price objective on United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Finally, Oppenheimer boosted their target price on United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $312.22.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.